Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
The Impact of Respiratory Strength Training in Individuals With Amyotrophic Lateral Sclerosis (ALS)
Verified date | January 2020 |
Source | University of Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Dysphagia (swallow impairment), dystussia (cough impairment) and respiratory impairment are
hallmark features of amyotrophic lateral sclerosis (ALS). These symptoms are the cause of
fatal aspiration, malnutrition and respiratory insufficiency that together account for 91.4%
of ALS mortality. Unfortunately, treatments to prolong and maintain these vital functions are
currently lacking. Although the use of exercise in ALS is controversial, recent evidence
suggests that mild to moderate intensity exercise applied early in the disease slows disease
progression, improves motor function, preserves motor neuron number, reduces muscle
hypoplasia, atrophy astrogliosis, and prolongs survival in animal models of ALS and human
clinical trials.
This research study is designed to determine the impact of respiratory strength training on
breathing, airway protection and swallowing in persons with Amyotrophic Lateral Sclerosis
(ALS).
Status | Completed |
Enrollment | 50 |
Est. completion date | February 7, 2019 |
Est. primary completion date | November 30, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 85 Years |
Eligibility |
Inclusion Criteria: - diagnosis of probable or definite Amyotrophic Lateral Sclerosis (ALS), - Amyotrophic Lateral Sclerosis Rating Scale Revised score greater than 34, - forced vital capacity greater than 70%, - cognition within normal limits as determined by Montreal assessment of cognition score >25 Exclusion Criteria: - allergies to barium, - tracheotomy or mechanical ventilation, - diaphragmatic pacer, - concurrent respiratory disease (e.g. COPD), - pregnant at the time of the study due to radiation exposure |
Country | Name | City | State |
---|---|---|---|
United States | UF Health Shands | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida | ALS Association |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Expiratory Pressure will be measured between the groups for a change from baseline to month 3 | Maximum expiratory pressure is a measure of force generating capabilities as assessed by having subjects quickly inhale then rapidly blow out air into a handheld manometer (Micro Mouth Pressure Meter). Three trails will be performed and the highest will be used. | Changes from baseline to month 3 | |
Primary | Maximum Inspiratory Pressure will be measured between the groups for a change from baseline to month 3 | Maximum inspiratory pressure is a measure of force generating capabilities as assessed by having subjects quickly inhale then rapidly blow out air into a handheld manometer (Micro Mouth Pressure Meter). Three trails will be performed and the highest will be used. | Changes from baseline to month 3 | |
Primary | Pulmonary function to measure the forced vital capacity (FVC) between the groups for a change from baseline to month 3 | Pulmonary Function testing will be performed using a micro pressure meter. The participant will perform a maximum inhalation and then slowly blow out air into the mouthpiece of the meter. The following measurement will be displayed on the meter after the exhalation is complete forced vital capacity (FVC) expressed as a percentage of predicted values. | Changes from baseline to month 3 | |
Primary | Sniff Nasal Inspiratory Pressure will be measured between the groups for a change from baseline to month 3 | Changes from baseline to month 3 | ||
Primary | Pulmonary function to measure the peak expiratory flow (PEF) will be measured between the groups for a change from baseline to month 3 | Pulmonary Function testing will be performed using a micro pressure meter. The participant will perform a maximum inhalation and then slowly blow out air into the mouthpiece of the meter. The following measurement will be displayed on the meter after the exhalation is complete peak expiratory flow (PEF) expressed as a percentage of predicted values. | Changes from baseline to month 3 | |
Primary | Pulmonary function to measure the forced expiratory volume (FEV1) will be measured between the groups for a change from baseline to month 3 | Pulmonary Function testing will be performed using a micro pressure meter. The participant will perform a maximum inhalation and then slowly blow out air into the mouthpiece of the meter. The following measurement will be displayed on the meter after the exhalation is complete forced expiratory volume (FEV1) expressed as a percentage of predicted values. | Changes from baseline to month 3 | |
Secondary | The Penetration-aspiration scale will be used to measure swallowing function | Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing. | Changes from baseline to month 3 | |
Secondary | Lingual strength will be measured between the groups for a change from baseline to month 3 | The Iowa Oral Pressure Instrument device will measure the peak performance of lingual strength a via the action of a bulb placed on the hard palate. To assess maximum anterior isometric pressure, the bulb will be placed on the roof of the mouth and the participant will raise his or her tongue to apply pressure to this bulb and then quickly release the tongue back into a neutral position. This repetitive tongue movement will be performed three times and values will be recorded. | Changes from baseline to month 3 | |
Secondary | Lingual endurance will be measured between the groups for a change from baseline to month 3 | The Iowa Oral Pressure Instrument device will measure the peak performance of maximum lingual endurance time by instructing the participant to place the bulb on the roof of the mouth and then apply and sustain pressure to the bulb for as long as he/she can at a threshold of 20% of the maximum anterior isometric pressure. The maximum lingual endurance time will also be recorded. | Changes from baseline to month 3 | |
Secondary | Voluntary cough function will be measured between the groups for a change from baseline to month 3 | Voluntary cough function will be assessed using an oral pneumotachograph, connected to a spirometer filter during voluntary cough production. The participant will be seated with a respiratory face-mask held in place by the examiner and instructed to complete three tidal breaths into the face-mask, airflow signal will be measured | Changes from baseline to month 3 | |
Secondary | Reflexive cough will be measured between the groups for a change from baseline to month 3 | Reflexive cough will be assessed using an oral pneumotachograph, differential pressure transducer, and have a side port with a one-way inspiratory valve for nebulizer connection. The nebulizer will deliver three randomized blocks of 0, 50, 100, 200, and 500 µM capsaicin. | Changes from baseline to month 3 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |